✦ LIBER ✦

PCN157 COST-EFFECTIVENESS OF UGT1A1 GENOTYPING IN IRINOTECAN CANCER THERAPY

✍ Scribed by M Obradovic; A Mrhar; M Kos

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost–effectiveness of UGT1A1 genotyping

✍ Obradovic, Marko; Mrhar, Ales; Kos, Mitja 📂 Article 📅 2008 🏛 Future Medicine 🌐 English ⚖ 319 KB

Indispensability of UGT1A1*6 genotyping

✍ Masashi Takano; Masafumi Kato; Tomoyuki Yoshikawa; Tomoko Goto; Kenichi Furuya; 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 102 KB

Genotype-directed, dose-finding study of

✍ Taroh Satoh; Takashi Ura; Yasuhide Yamada; Kentaro Yamazaki; Toshimasa Tsujinaka 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

Phase II and UGT1A1 genotype study of ir

✍ Jo, J-C; Lee, J-L; Ryu, M-H; Chang, H M; Kim, M; Lee, H J; Kim, H-S; Shin, J-G; 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 357 KB

Uridine Diphosphate Glucuronosyltransfer

✍ O'Dwyer, P. J. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 82 KB

UGT1A1*28 genotype and irinotecan dosage

✍ Kweekel, D M; Gelderblom, H; Van der Straaten, T; Antonini, N F; Punt, C J A; Gu 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 159 KB